Pardes Biosciences (PRDS) to Be Acquired by MediPacific for $2.02-$2.19 Per Share
by Nicholas Alan Clayton on 2023-07-17 at 8:46am

Pardes Biosciences (NASDAQ:PRDS), which combined with FS Development Corp. II in December 2021, announced that it has agreed to be acquired by MediPacific for $2.02 to $2.19 per share for a premium of 8%-17% over its last closing price.

A tender offer for the company will launch on July 28 to acquire all outstanding Pardes shares within this price range. A MediPacific subsidiary will also receive a contingent value right (CVR) promising it 80% of net proceeds from any license of Pardes assets over the first five years following close.

Pardes’ main drug candidate Pomotrelvir is designed to inhibit the reproduction of coronavirus cells. It demonstrated potential effectiveness in Phase I trials against recent COVID-19 variant Omicron as well as the MERS and SARS variants discovered earlier.

But, its initial readouts from Phase II trials dropped in April and it did not meet its primary endpoint in producing better outcomes than a placebo.

Patients were otherwise healthy, vaccinated adults that had been infected with COVID-19 and although patients in both groups had dropping viral loads and improved health, the data indicated it was likely the vaccine rather than Pomotrelvir doing most of the work.

Pardes stock was in a slump even before these results, however. Having hit a post-close high of $16.88 in January 2022, it has traded below $5 since June 2022, despite being well-funded with just 1.2% redemptions from FS II’s $200 million trust.

But, as the world moved on from COVID, the market appears to have moved on from potential breakthroughs in treating it as well. Having hit an initial dead end with Pomotrelvir’s Phase II, the company announced it would suspend its development and seek out strategic alternatives.

From this standpoint, Pardes may be considered fortunate that it will still be effectively valued at about $130 million in this take-private.


Recent Posts
by Marlena Haddad on 2023-12-08 at 1:59pm

Mobiv Acquisition Corp. (NASDAQ:MOBV) announced this afternoon that it has closed its combination with EV motorcycle-maker SRIVARU. Shareholders originally approved the deal at a special meeting held back on September 28, but at that time, the parties expected the transaction to take just a week to close. Redemptions whittled Mobiv’s IPO share pool of 10,005,000 down...

by Nicholas Alan Clayton on 2023-12-08 at 11:12am

Achari Ventures I (NASDAQ:AVHI) has entered into a definitive agreement to combine with medtech firm Vaso Corporation at an equity value of $176 million, or 19.5x its 2022 adjusted EBITDA. Wuxi, China-based Vaso provides IT services and sales support to medical device manufacturers. The combined company is expected to trade on the Nasdaq under the...

by Marlena Haddad on 2023-12-08 at 10:27am

EF Hutton Acquisition Corp. I (NASDAQ:EFHT) announced this morning that its shareholders have approved its business combination with E.C.D. Auto Design. At the meeting, there were 5,089,203 shares of common stock, representing approximately 76.82% of the issued and outstanding shares of common stock, present. In connection with the meeting, the company’s stockholders holding 3,470,945 shares,...

by Marlena Haddad on 2023-12-08 at 9:42am

Legato Merger Corp. III (NYSE:LEGT) filed for a $175 million IPO yesterday afternoon, becoming the fourth SPAC to file this week. While the other three SPACs that filed their S-1s earlier this week intend to pursue targets in the financial services and biotech industries, Legato III, similar to the earlier Legato SPACs, will focus on...

by Nicholas Alan Clayton on 2023-12-08 at 7:48am

At the SPAC of Dawn This week ends with an unusually busy earnings calendar as 172 US-listed companies report quarterly figures today. Among them is Exela Technologies (NASDSAQ:XELA), which completed a combination with Quinpario 2 in 2017. The billing software company has gone on to do another SPAC deal on November 29, this time spinning...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved